

CLAIMS

1. An agent for treating or preventing a low-turnover bone disease, comprising as an active ingredient a spherical activated carbon.
2. The agent according to claim 1, wherein the low-turnover bone disease is renal osteodystrophy or adynamic bone disease.
3. The agent according to claim 2, wherein the adynamic bone disease is adynamic bone disease in conservative chronic kidney disease or adynamic bone disease in renal osteodystrophy in a patient under treatment with dialysis.
4. The agent according to any one of claims 1 to 3, wherein a particle size of the spherical activated carbon is 0.01 to 2 mm.
5. A pharmaceutical composition for treating or preventing a low-turnover bone disease, comprising a spherical activated carbon and a pharmaceutically or veterinarily acceptable carrier or diluent.
6. The pharmaceutical composition according to claim 5, wherein the low-turnover bone disease is renal osteodystrophy or adynamic bone disease.
7. The pharmaceutical composition according to claim 6, wherein the adynamic bone disease is adynamic bone disease in conservative chronic kidney disease, or adynamic bone disease in renal osteodystrophy in a patient under treatment with dialysis.
8. The pharmaceutical composition according to any one of claims 5 to 6, wherein a particle size of the spherical activated carbon is 0.01 to 2 mm.
9. A method for treating or preventing a low-turnover bone disease, comprising administering to a subject in need thereof a spherical activated carbon in an amount effective thereof.
10. The method according to claim 9, wherein the low-turnover

bone disease is renal osteodystrophy or adynamic bone disease.

11. The method according to claim 10, wherein the adynamic bone disease is adynamic bone disease in conservative chronic kidney disease, or adynamic bone disease in renal osteodystrophy in a patient under treatment with dialysis.

12. The method according to any one of claims 9 to 11, wherein a particle size of the spherical activated carbon is 0.01 to 2 mm..

13. Use of a spherical activated carbon in the manufacture of an agent for treating or preventing a low-turnover bone disease or a pharmaceutical composition for treating or preventing a low-turnover bone disease.

14. Use according to claim 13, wherein the low-turnover bone disease is renal osteodystrophy or adynamic bone disease.

15. Use according to claim 14, wherein the adynamic bone disease is adynamic bone disease in conservative chronic kidney disease, or adynamic bone disease in renal osteodystrophy in a patient under treatment with dialysis.

16. Use according to any one of claims 13 to 15, wherein a particle size of the spherical activated carbon is 0.01 to 2 mm.

**BEST AVAILABLE COPY**

**BEST AVAILABLE COPY**